These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15526004)

  • 1. Genetic risk factors for infection in patients with early rheumatoid arthritis.
    Hughes LB; Criswell LA; Beasley TM; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Genes Immun; 2004 Dec; 5(8):641-7. PubMed ID: 15526004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.
    Mahmoud I; Moalla M; Ben Tekaya A; Bouden S; Rouached L; Tekaya R; Saidane O; Gorji Y; Elleuch M; Laatar A; Hamdi W; Abdelmoula L; Sfar I
    Drug Metab Pers Ther; 2023 Jun; 38(2):155-162. PubMed ID: 36919284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
    Kang CP; Lee KW; Yoo DH; Kang C; Bae SC
    Rheumatology (Oxford); 2005 Apr; 44(4):547-52. PubMed ID: 15695296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2015; 33(5):647-54. PubMed ID: 26314337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
    Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
    J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphotoxin-α 252 A>G polymorphism: a link between disease susceptibility and dyslipidemia in rheumatoid arthritis?
    Santos MJ; Fernandes D; Caetano-Lopes J; Perpetuo IP; Vidal B; Canhao H; Fonseca JE
    J Rheumatol; 2011 Jul; 38(7):1244-9. PubMed ID: 21459939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B.
    Morgan AW; Barrett JH; Griffiths B; Subramanian D; Robinson JI; Keyte VH; Ali M; Jones EA; Old RW; Ponchel F; Boylston AW; Situnayake RD; Markham AF; Emery P; Isaacs JD
    Arthritis Res Ther; 2006; 8(1):R5. PubMed ID: 16356189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis.
    Asano K; Matsumoto T; Umeno J; Hirano A; Esaki M; Hosono N; Matsui T; Kiyohara Y; Nakamura Y; Kubo M; Kitazono T
    Inflamm Bowel Dis; 2013 Sep; 19(10):2061-8. PubMed ID: 23917248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.
    Okuyama A; Nagasawa H; Suzuki K; Kameda H; Kondo H; Amano K; Takeuchi T
    Ann Rheum Dis; 2011 Feb; 70(2):299-304. PubMed ID: 20980704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis.
    Song GG; Lee YH
    Mol Biol Rep; 2013 Aug; 40(8):4985-93. PubMed ID: 23649770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF-α and risk of infections: the experience in one center.
    Maruotti N; D'Onofrio F; Neve A; Santoro N; Corrado A; Cantatore FP
    Panminerva Med; 2014 Mar; 56(1):31-4. PubMed ID: 24637471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
    Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype.
    Newton J; Brown MA; Milicic A; Ackerman H; Darke C; Wilson JN; Wordsworth BP; Kwiatkowski D
    Arthritis Rheum; 2003 Jan; 48(1):90-6. PubMed ID: 12528108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.